Aptose Biosciences (TSE:APS) Sets New 12-Month Low at $1.00

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO)’s share price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as C$1.00 and last traded at C$1.05, with a volume of 2100 shares changing hands. The stock had previously closed at C$1.02.

Aptose Biosciences Trading Down 3.8 %

The company has a debt-to-equity ratio of 14.27, a quick ratio of 5.41 and a current ratio of 0.78. The stock’s 50-day simple moving average is C$1.46 and its 200-day simple moving average is C$2.19. The firm has a market capitalization of C$16.47 million, a PE ratio of -0.10 and a beta of 1.47.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last released its earnings results on Tuesday, May 14th. The biotechnology company reported C($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of C($1.12) by C$0.14. As a group, sell-side analysts expect that Aptose Biosciences Inc. will post -0.59 EPS for the current fiscal year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.